For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in PerkinElmer ten years ago? It may not have been easy to hold on to PKI for all that time, but if you did, how much would your investment be worth today?
PerkinElmer's Business In-Depth
With that in mind, let's take a look at PerkinElmer's main business drivers.
Headquartered in Waltham, MA, PerkinElmer, Inc. provides scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental testing, chemical, and general industrial markets worldwide.
For the Diagnostics market, the company offers products that are used to detect genetic disorders from pre-conception to early childhood. The company also provides digital x-ray flat panel detectors and infectious disease testing solutions. For the Research market, the company offers reagents, liquid handling and detection, and imaging technologies that are used by researchers in the drug discovery process.
In the Discovery & Analytical Solutions (DAS) segment, PerkinElmer has two operating segments – Human Health and Environmental Health. In recent past, the company realigned its business structure. OneSource, the company’s multivendor laboratory service business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment.
The Human Health segment focuses on developing diagnostics, tools and applications, which help to detect diseases earlier and more accurately. The Human Health segment serves two end markets: diagnostics and research.
The Environmental Health segment offers products and services that help in producing safer food and consumer products, securing environment and using energy more efficiently. The segment serves three end markets - laboratory services, environmental and Industrial. The company’s environmental solutions help in maintaining the wellbeing of air, water, soil and food. PerkinElmer’s environmental applications help its customers comply with regulatory requirements and maintain industry standards by detecting harmful substances in water, adulterants in food, toxic metals in toys, counterfeits in medicine and many other consumer products.
2020 at a Glance
In 2020, the company posted revenues worth $3.78 billion, up 31.2% on a year-over-year basis. In 2020, Discovery & Analytical Solutions (DAS) revenues totaled $1.72 billion (46% of net revenues) and Diagnostics’ revenues came in at $2.07 billion (54%).
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in PerkinElmer a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in July 2011 would be worth $5,627.95, or a 462.79% gain, as of July 8, 2021, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 222.06% and the price of gold went up 12.32% over the same time frame.
Going forward, analysts are expecting more upside for PKI.
PerkinElmer witnessed robust core segmental performance in the first quarter of 2021. Strong growth in Europe and United States is also encouraging. In March 2021, PerkinElmer completed the acquisition of Oxford Immunotec Global Plc, which will enable the company to expand its portfolio of advanced infectious disease testing solutions by including tuberculosis detection product line. Notably, COVID-related products and services contributed $550 million in the first quarter. Expansion in both margins buoy optimism. A raised full-year 2021 outlook is a key highlight. A strong liquidity position is an added plus. PerkinElmer’s results in the first quarter were better-than-expected. Over the past three months, the stock outperformed its sector. Yet, PerkinElmer continues to make acquisitions, which increases integration risks.
Shares have gained 9.65% over the past four weeks and there have been 3 higher earnings estimate revisions for fiscal 2021 compared to none lower. The consensus estimate has moved up as well.
Image: Bigstock
If You Invested $1000 in PerkinElmer 10 Years Ago, This Is How Much You'd Have Now
For most investors, how much a stock's price changes over time is important. Not only can it impact your investment portfolio, but it can also help you compare investment results across sectors and industries.
FOMO, or the fear of missing out, also plays a role in investing, particularly with tech giants and popular consumer-facing stocks.
What if you'd invested in PerkinElmer ten years ago? It may not have been easy to hold on to PKI for all that time, but if you did, how much would your investment be worth today?
PerkinElmer's Business In-Depth
With that in mind, let's take a look at PerkinElmer's main business drivers.
Headquartered in Waltham, MA, PerkinElmer, Inc. provides scientific instruments, consumables, and services to pharmaceutical, biomedical, environmental testing, chemical, and general industrial markets worldwide.
For the Diagnostics market, the company offers products that are used to detect genetic disorders from pre-conception to early childhood. The company also provides digital x-ray flat panel detectors and infectious disease testing solutions. For the Research market, the company offers reagents, liquid handling and detection, and imaging technologies that are used by researchers in the drug discovery process.
In the Discovery & Analytical Solutions (DAS) segment, PerkinElmer has two operating segments – Human Health and Environmental Health. In recent past, the company realigned its business structure. OneSource, the company’s multivendor laboratory service business that serves the life sciences end market, was moved from the Environmental Health segment into the Human Health segment.
The Human Health segment focuses on developing diagnostics, tools and applications, which help to detect diseases earlier and more accurately. The Human Health segment serves two end markets: diagnostics and research.
The Environmental Health segment offers products and services that help in producing safer food and consumer products, securing environment and using energy more efficiently. The segment serves three end markets - laboratory services, environmental and Industrial. The company’s environmental solutions help in maintaining the wellbeing of air, water, soil and food. PerkinElmer’s environmental applications help its customers comply with regulatory requirements and maintain industry standards by detecting harmful substances in water, adulterants in food, toxic metals in toys, counterfeits in medicine and many other consumer products.
2020 at a Glance
In 2020, the company posted revenues worth $3.78 billion, up 31.2% on a year-over-year basis. In 2020, Discovery & Analytical Solutions (DAS) revenues totaled $1.72 billion (46% of net revenues) and Diagnostics’ revenues came in at $2.07 billion (54%).
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in PerkinElmer a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in July 2011 would be worth $5,627.95, or a 462.79% gain, as of July 8, 2021, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 222.06% and the price of gold went up 12.32% over the same time frame.
Going forward, analysts are expecting more upside for PKI.
PerkinElmer witnessed robust core segmental performance in the first quarter of 2021. Strong growth in Europe and United States is also encouraging. In March 2021, PerkinElmer completed the acquisition of Oxford Immunotec Global Plc, which will enable the company to expand its portfolio of advanced infectious disease testing solutions by including tuberculosis detection product line. Notably, COVID-related products and services contributed $550 million in the first quarter. Expansion in both margins buoy optimism. A raised full-year 2021 outlook is a key highlight. A strong liquidity position is an added plus. PerkinElmer’s results in the first quarter were better-than-expected. Over the past three months, the stock outperformed its sector. Yet, PerkinElmer continues to make acquisitions, which increases integration risks.
Shares have gained 9.65% over the past four weeks and there have been 3 higher earnings estimate revisions for fiscal 2021 compared to none lower. The consensus estimate has moved up as well.